CPAP or BiPAP for Motion Mitigation During Radiotherapy (SISTER)
Primary Purpose
Radiotherapy Side Effect, NSCLC, Esophageal Cancer
Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
CPAP
Sponsored by
About this trial
This is an interventional other trial for Radiotherapy Side Effect focused on measuring BiPAP, CPAP, Mechanical ventilation
Eligibility Criteria
Inclusion Criteria:
- Age ≥18 years
- Stage III/IV (N)SCLC, esophageal cancer or malignant lymphoma that will be treated with curative intent
- WHO 0-2.
- Written informed consent
Exclusion Criteria:
- Facial deformations so that facial mask is impossible to fit
- Noncompliance with any of the inclusion criteria.
- Planned for radiotherapy with fraction dose ≥3 Gy.
- Severe heart failure (LVEF<30%)
Sites / Locations
- University Medical Center GroningenRecruiting
Outcomes
Primary Outcome Measures
Lung volume changes induced by the use of mechanical ventilation
The primary objective is to evaluate the lung volume changes (in cm3) induced by the use of mechanical ventilation
Secondary Outcome Measures
Feasibility of mechanical ventilation
Feasibility is expressed as a score (using a Visual Analoge Scale)
Feasibility of mechanical ventilation
Feasibility is expressed as the duration (minutes) the participant can undergo mechanical ventilation
Full Information
NCT ID
NCT04986293
First Posted
July 1, 2021
Last Updated
November 23, 2022
Sponsor
University Medical Center Groningen
1. Study Identification
Unique Protocol Identification Number
NCT04986293
Brief Title
CPAP or BiPAP for Motion Mitigation During Radiotherapy
Acronym
SISTER
Official Title
Continuous and Bi-level Positive Airway Pressure for Motion Mitigation of Intra-thoracic Tumors Treated With Radiotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Medical Center Groningen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
When using highly conformal radiotherapy techniques, such as proton therapy, a controlled breathing pattern and a minimal breathing amplitude could greatly benefit the treatment of mobile tumors. This reduction in tumor motion may be achieved with the use of a ventilator that is able to regulate and modulate the breathing pattern. CPAP provides a constant level of positive airway pressure. Compared to spontaneous breathing, the use of CPAP increased lung volume and can result in a significant decrease in tumor movement and a significant decrease in both mean lung and mean heart radiation dose. These results were found in patients treated for limited stage disease, it is not clear if this approach is feasible for patients with more advanced stage of disease that undergo radiotherapy with curative intent.
With Bilevel Positive Airway Pressure (BiPAP), tidal volume excursions are determined by the pressure difference between the set inspiratory positive airway pressure (IPAP) and the set expiratory positive airway pressure (EPAP). This mode of ventilation increases lung volume comparable to CPAP, but also to control tidal volumes and breathing frequency. However, BiPAP has never been studied in the setting of motion mitigation during radiotherapy and BiPAP might be more difficult to adjust to for patients compared to CPAP. Therefore, the current study is proposed to evaluate whether or not CPAP or BiPAP is of benefit in patients that undergo radiotherapy for larger intra-thoracic tumor volumes.
Detailed Description
The study will follow a 2-step approach.
First (Phase 1, n=10), the feasibility of short-term use of CPAP and BiPAP and its effects on (regional) lung volumes, tidal volumes and breathing frequency will be investigated in patients with intra-thoracic tumors who are planned for radiotherapy. This is necessary to select the best setting of CPAP or BiPAP with which minimal tumor motion is expected (and that is feasible for the patient).
In the second phase (n=21), the particular setting found in fase 1 is investigated: weekly repeated radiotherapy planning (4D) CT scans with and without CPAP/BiPAP will be aquired to evaluate the influence on tumor motion and dose to the target and organs at risk. Radiotherapy will be deliverd according to local protocol without the use of CPAP/BiPAP.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Radiotherapy Side Effect, NSCLC, Esophageal Cancer, Malignant Lymphoma
Keywords
BiPAP, CPAP, Mechanical ventilation
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
31 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
CPAP
Other Intervention Name(s)
BiPAP
Intervention Description
Different settings of CPAP and BiPAP will be tested using a home mechanical ventilator
Primary Outcome Measure Information:
Title
Lung volume changes induced by the use of mechanical ventilation
Description
The primary objective is to evaluate the lung volume changes (in cm3) induced by the use of mechanical ventilation
Time Frame
2-3 hours of measurement (only once)
Secondary Outcome Measure Information:
Title
Feasibility of mechanical ventilation
Description
Feasibility is expressed as a score (using a Visual Analoge Scale)
Time Frame
once every week up to a maximum of 5 consecutive weeks (depending on the duration of the course of radiotherapy)
Title
Feasibility of mechanical ventilation
Description
Feasibility is expressed as the duration (minutes) the participant can undergo mechanical ventilation
Time Frame
once every week up to a maximum of 5 consecutive weeks (depending on the duration of the course of radiotherapy)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥18 years
Stage III/IV (N)SCLC, esophageal cancer or malignant lymphoma that will be treated with curative intent
WHO 0-2.
Written informed consent
Exclusion Criteria:
Facial deformations so that facial mask is impossible to fit
Noncompliance with any of the inclusion criteria.
Planned for radiotherapy with fraction dose ≥3 Gy.
Severe heart failure (LVEF<30%)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robin Wijsman
Phone
+31503612711
Email
info@rt.umcg.nl
First Name & Middle Initial & Last Name or Official Title & Degree
J. Elshof
Phone
+31503611036
Email
j.elshof@umcg.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robin Wijsman
Organizational Affiliation
UMCG
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Medical Center Groningen
City
Groningen
ZIP/Postal Code
9700 RB
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robin Wijsman
Phone
+31503612711
Email
info@rt.umcg.nl
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
CPAP or BiPAP for Motion Mitigation During Radiotherapy
We'll reach out to this number within 24 hrs